These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 9508177)

  • 41. Topotecan in pediatric patients with recurrent and progressive solid tumors: a Pediatric Oncology Group phase II study.
    Nitschke R; Parkhurst J; Sullivan J; Harris MB; Bernstein M; Pratt C
    J Pediatr Hematol Oncol; 1998; 20(4):315-8. PubMed ID: 9703003
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Phase I trial of multiple cycles of high-dose carboplatin, paclitaxel, and topotecan with peripheral-blood stem-cell support as front-line therapy.
    Schilder RJ; Gallo JM; Millenson MM; Bookman MA; Weiner LM; Rogatko A; Rogers B; Padavic-Shallers K; Boente M; Rosenblum N; Adams AL; Ciccotto S; Ozols RF
    J Clin Oncol; 2001 Feb; 19(4):1183-94. PubMed ID: 11181685
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Vinorelbine and low-dose cyclophosphamide in the treatment of pediatric sarcomas: pilot study for the upcoming European Rhabdomyosarcoma Protocol.
    Casanova M; Ferrari A; Bisogno G; Merks JH; De Salvo GL; Meazza C; Tettoni K; Provenzi M; Mazzarino I; Carli M
    Cancer; 2004 Oct; 101(7):1664-71. PubMed ID: 15378498
    [TBL] [Abstract][Full Text] [Related]  

  • 44. High-dose topotecan, melphalan, and cyclophosphamide (TMC) with stem cell support: a new regimen for the treatment of advanced ovarian cancer.
    Donato ML; Gershenson DM; Wharton JT; Ippoliti CM; Aleman AS; Bodurka-Bevers D; Bevers MW; Burke TW; Levenback CF; Wolf JK; Freedman RS; Bast RC; Gajewski JL; Champlin RE
    Gynecol Oncol; 2001 Sep; 82(3):420-6. PubMed ID: 11520135
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Phase I study of topotecan for pediatric patients with malignant solid tumors.
    Pratt CB; Stewart C; Santana VM; Bowman L; Furman W; Ochs J; Marina N; Kuttesch JF; Heideman R; Sandlund JT
    J Clin Oncol; 1994 Mar; 12(3):539-43. PubMed ID: 8120551
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A phase 1 study of simvastatin in combination with topotecan and cyclophosphamide in pediatric patients with relapsed and/or refractory solid and CNS tumors.
    Cash T; Jonus HC; Tsvetkova M; Beumer JH; Sadanand A; Lee JY; Henry CJ; Aguilera D; Harvey RD; Goldsmith KC
    Pediatr Blood Cancer; 2023 Aug; 70(8):e30405. PubMed ID: 37158620
    [TBL] [Abstract][Full Text] [Related]  

  • 47. High-dose topotecan with granulocyte-colony stimulating factor in fluoropyrimidine-refractory colorectal cancer: a phase II and pharmacodynamic study.
    Rowinsky EK; Baker SD; Burks K; O'Reilly S; Donehower RC; Grochow LB
    Ann Oncol; 1998 Feb; 9(2):173-80. PubMed ID: 9553662
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Pilot study of topotecan and high-dose cyclophosphamide for resistant pediatric solid tumors.
    Kushner BH; Kramer K; Meyers PA; Wollner N; Cheung NK
    Med Pediatr Oncol; 2000 Nov; 35(5):468-74. PubMed ID: 11070479
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Phase I trial and pharmacologic trial of sequences of paclitaxel and topotecan in previously treated ovarian epithelial malignancies: a Gynecologic Oncology Group study.
    O'Reilly S; Fleming GF; Barker SD; Walczak JR; Bookman MA; McGuire WP; Schilder RJ; Alvarez RD; Armstrong DK; Horowitz IR; Ozols RF; Rowinsky EK
    J Clin Oncol; 1997 Jan; 15(1):177-86. PubMed ID: 8996140
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Phase II study of temozolomide in combination with topotecan (TOTEM) in relapsed or refractory neuroblastoma: a European Innovative Therapies for Children with Cancer-SIOP-European Neuroblastoma study.
    Di Giannatale A; Dias-Gastellier N; Devos A; Mc Hugh K; Boubaker A; Courbon F; Verschuur A; Ducassoul S; Malekzadeh K; Casanova M; Amoroso L; Chastagner P; Zwaan CM; Munzer C; Aerts I; Landman-Parker J; Riccardi R; Le Deley MC; Geoerger B; Rubie H
    Eur J Cancer; 2014 Jan; 50(1):170-7. PubMed ID: 24021349
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Protracted intermittent schedule of topotecan in children with refractory acute leukemia: a pediatric oncology group study.
    Furman WL; Stewart CF; Kirstein M; Kepner JL; Bernstein ML; Kung F; Vietti TJ; Steuber CP; Becton DL; Baruchel S; Pratt C
    J Clin Oncol; 2002 Mar; 20(6):1617-24. PubMed ID: 11896112
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Phase I and pharmacologic study of high doses of the topoisomerase I inhibitor topotecan with granulocyte colony-stimulating factor in patients with solid tumors.
    Rowinsky EK; Grochow LB; Sartorius SE; Bowling MK; Kaufmann SH; Peereboom D; Donehower RC
    J Clin Oncol; 1996 Apr; 14(4):1224-35. PubMed ID: 8648378
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A Phase I-II study of sequential administration of topotecan and oral etoposide (toposiomerase I and II inhibitors) in the treatment of patients with small cell lung carcinoma.
    Mok TS; Wong H; Zee B; Yu KH; Leung TW; Lee TW; Yim A; Chan AT; Yeo W; Chak K; Johnson P
    Cancer; 2002 Oct; 95(7):1511-9. PubMed ID: 12237920
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Combination docetaxel/cyclophosphamide in patients with advanced solid tumors.
    Valero V
    Oncology (Williston Park); 1997 Aug; 11(8 Suppl 8):34-6. PubMed ID: 9364540
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Phase I study of combined pegylated liposomal doxorubicin with protracted daily topotecan for ovarian cancer.
    Mirchandani D; Hochster H; Hamilton A; Liebes L; Yee H; Curtin JP; Lee S; Sorich J; Dellenbaugh C; Muggia FM
    Clin Cancer Res; 2005 Aug; 11(16):5912-9. PubMed ID: 16115933
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Sequential topotecan and oral etoposide in recurrent ovarian carcinoma pretreated with platinum-taxane. Results from a multicenter phase I/II study.
    Gronlund B; Engelholm SA; Horvath G; Mäenpää J; Ridderheim M
    Cancer; 2005 Apr; 103(7):1388-96. PubMed ID: 15719439
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A dose-intensive, cyclophosphamide-based regimen for the treatment of recurrent/progressive or advanced solid tumors of childhood: a report from the Australia and New Zealand Children's Cancer Study Group.
    Carpenter PA; White L; McCowage GB; Nayanar V; Toogood I; Shaw PJ; Lockwood L; Tiedemann K
    Cancer; 1997 Aug; 80(3):489-96. PubMed ID: 9241083
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A phase 1 study of nifurtimox in patients with relapsed/refractory neuroblastoma.
    Saulnier Sholler GL; Bergendahl GM; Brard L; Singh AP; Heath BW; Bingham PM; Ashikaga T; Kamen BA; Homans AC; Slavik MA; Lenox SR; Higgins TJ; Ferguson WS
    J Pediatr Hematol Oncol; 2011 Jan; 33(1):25-30. PubMed ID: 21063221
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A study of sequential high dose cyclophosphamide and high dose carboplatin with peripheral stem-cell rescue in resistant or recurrent pediatric brain tumors.
    Foreman NK; Schissel D; Le T; Strain J; Fleitz J; Quinones R; Giller R
    J Neurooncol; 2005 Jan; 71(2):181-7. PubMed ID: 15690136
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Phase I trial of tirapazamine and cyclophosphamide in children with refractory solid tumors: a pediatric oncology group study.
    Aquino VM; Weitman SD; Winick NJ; Blaney S; Furman WL; Kepner JL; Bonate P; Krailo M; Qu W; Bernstein M
    J Clin Oncol; 2004 Apr; 22(8):1413-9. PubMed ID: 15084615
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.